zurück zur Startseite
Zentrale Tel.: 06221-560
Translational Lung Research Center Heidelberg

Georg F. Hoffmann, M.D.

 

Professor of Pediatrics and Chairman of the University Childrens Hospital Heidelberg

Head of the Newborn Screening Center of South-West Germany (Baden-Württemberg, Rheinland-Pfalz, Saarland)
Vice Dean of the Medical Faculty of the Ruprecht-Karls-University Heidelberg

 

Heidelberg University Hospital

Im Neuenheimer Feld 430
69120 Heidelberg


Phone:+49 (0) 6221 56-4100

Fax: +49 (0) 6221 56-4339

Opens window for sending emailE-Mail

Opens external link in new windowHomepage

Research Interests:

  • Development of screening strategies for cystic fibrosis patients

  • Pathophysiology and treatment of metabolic diseases

  • Rare genetic disorders

Short CV

1976-1984Study of Medicine at the Universities of Göttingen, F.R.G., and Birmingham, U.K
1984Dissertation (M.D.) at the University of Göttingen, summa cum laude
1984-1986Postdoctoral Fellow, Division of Biochemical Genetics, Department of Pediatrics, University of California, San Diego, U.S.A., (L. Sweetman, Ph. D. and W. L. Nyhan, M.D., Ph.D.)
1984-1991Clinical training in Pediatrics at the University Children’s Hospitals of University of California, San Diego, U.S.A., Göttingen and Heidelberg (1984-1991)
1992-1994Group Leader and Head of the Division of Metabolic Diseases at the University Childrens Hospital Heidelberg
1994-1999Professor of Pediatrics at the Philipps-University of Marburg and Head of the Department of Neuropediatrics and Metabolic Diseases
Since 1999Professor of Pediatrics and Chairman of the University Childrens Hospital Heidelberg

Honours & Awards

1986 Noel Raine Award of the "Society for the Study of Inborn Errors of Metabolism"
1994 SSIEM Award of the "Society for the Study of Inborn Errors of Metabolism"
2000 Science 4 Life 2000      

Projects

There is agreement on the benefits of newborn screening (NBS) for cystic fibrosis (CF) in terms of improved growth and survival, less lung damage, lower burden of care, less parental stress compared to a delayed clinical diagnosis, and reduced treatment costs. These results led to a widespread implementation of CF NBS in a number of developed countries. In most countries quantitation of IRT was combined with CFTR mutation analysis for CF NBS. However, in a number of countries legal restrictions or ethical motivated debates impede the implementation of any genetic screening strategies (e.g. Austria, Germany). Disadvantages of genetic NBS for CF have driven the development of an alternative, biochemical method using immunoreactive trypsin (IRT) as first, and pancreatitis associated protein (PAP) as second tier. We compare and optimize different IRT/PAP protocols which are tested around Europe. Our aim is an optimized IRT/PAP protocol representing a reliable and cost-effective alternative to an IRT/DNA based screening that avoids inherent ethical problems related to detection of healthy carriers and CF patients with equivocal diagnosis.

Team

Post-doctoral fellows

Dr. Sven Sauer, Ph.D.
Opens window for sending emailE-Mail

 

Dr. Dirk Kohlmüller, Ph.D. 
Opens window for sending emailE-Mail

 

M.D. Students

Ms. Katrin Zangerl
Opens window for sending emailE-Mail

Selected Publications

  1. Thiel C, Meßner-Schmitt D, Hoffmann GF, Körner C. 2012 Screening for congenital disorders of glycosylation in the first weeks of life. J Inherit Metab Dis [EPub ahead of print]
  2. Loeber JG, Burgard P, Cornel MC, Rigter T, Weinreich SS, Rupp K, Hoffmann GF, Vittozzi L. 2012 Newborn Screening programmes in Europe; arguments and efforts regarding harmonization. Part 1 – From blood spot to screening result. J Inherit Metab Dis 35: 603-611
  3. Burgard P, Rupp K, Lindner M, Haege G, Rigter T, Weinreich SS, Loeber JG, Taruscio D, Vittozzi L, Cornel MC, Hoffmann GF. 2012 Newborn Screening programmes in Europe; arguments and efforts regarding harmonization. Part 2 – From screening laboratory results to treatment, follow-up and quality assurance. J Inherit Metab Dis 35: 613-625
  4. Burgard P, Cornel M, di Filippo F, Haege G, Hoffmann GF, Lindner M, Loeber JG, Rigter T, Rupp K, Taruscio D, Weinreich S, Vittozzi L. 2012 Report on the practices of newborn screening for rare disorders implemented in Member States of the European Union, Candidate, Potential Candidate and EFTA Countries. Opens external link in new windowhttp://www.iss.it/cnmr/prog/cont.php?id=1621&lang=1&tipo=64
  5. Cornel M, Rigter T, Weinreich S, Burgard P, Hoffmann GF, Lindner M, Loeber JG, Rupp K, Taruscio D, Vittozzi L. 2012 Newborn screening in Europe. Expert Opinion document.
  6. Opens external link in new windowhttp://www.iss.it/cnmr/prog/cont.php?id=1621&lang=1&tipo=64
  7. Vittozzi L, Burgard P, Cornel M, Hoffmann GF, Lindner M, Loeber JG, Rigter T, Rupp K, Taruscio D, Weinreich S. 2012 Executive Report to the European Commission on newborn screening in the European Union. Opens external link in new windowhttp://www.iss.it/cnmr/prog/cont.php?id=1621&lang=1&tipo=64
  8. Simonetti GD, Schwertz R, Klett M, Hoffmann GF, Schaefer F, Wühl E. 2011 Determinants of blood pressure in preschool children. The role of parental smoking. Circulation 123: 292 – 298
  9. Lindner M, Gramer G, Haege G, Fang-Hoffmann J, Schwab KO, Tacke U, Trefz FK, Mengel E, Wendel U, Leichsenring M, Burgard P, Hoffmann GF. 2011 Efficacy and outcome of expanded newborn screening for metabolic diseases – Report of 10 years from South-West Germany. Orphanet Journal of Rare Disease 6:44. Opens external link in new windowhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3141366/
  10. Sommerburg O, Lindner M, Muckenthaler M, Kohlmueller D, Leible S, Feneberg R, Kulozik AE, Mall MA, Hoffmann GF. 2010 Initial evaluation of a biochemical cystic fibrosis newborn screening by sequential analysis of immunoreactive trypsinogen and pancreatitis-associated protein (IRT/PAP) as a strategy that does not involve DNA testing in a Northern European population. J Inherit Metab Dis 33: (Suppl 2): S263-S271
Select languageSelect language
Print Diese Seite per E-Mail weiterempfehlen